CLAIMS

1. Use of a therapeutic composition comprising allogeneic Th1 cells in the manufacture of a medicament for decreasing the immunosuppressive activity of Treg cells in a patient, wherein decreasing and/or inhibiting the activity of the Treg cells: i) reduces the immune tolerance of disease antigens in the patient; ii) induces a therapeutic effect against a disease in the patient; or iii) reduces the immunosuppressive functions in the patient.

2. The use according to claim 1 wherein the Treg cells are CD4+CD25+FoxP3+.

3. The use according to claim 1 wherein the suppressive activity of the Treg cells is inhibited by decreasing the conversion of naïve T cells (CD4CD25-FoxP3-) to iTreg cells.

4. The use according to claim 1 wherein the suppressive activity of the Treg cells is by inhibition of nTreg cells.

5. The use according to claim 1 wherein the therapeutic composition comprises allogeneic emTh1 cells.

6. The use according to claim 1 wherein the therapeutic composition further comprises disease antigens or lysates associated with the disease antigens~~, and wherein the therapeutic composition optionally further comprises chaperone rich cell lysate of the disease antigens~~.

7. The use according to claim 1 wherein the therapeutic composition further comprises: i) IFNγ; ii) components that interact and reduce the activity of TGF-beta; or CD40L.

8. The use according to claim 1 wherein the disease is cancer or an infectious disease.

9. Use of activated Th1 cells and a source of disease antigens in the manufacture of a medicament for suppressing immune tolerance and promoting a therapeutic effect in a patient with a disease, wherein the Th1 cells and the disease antigens are to be administered at the same location.

10. The use according to claim 9 wherein: the Th1 cells and the disease antigens are to be administered by intradermal injections and/or the activated Th1 cells are to be administered prior to the source of disease antigens.

11. The use according to claim 9 wherein the Th1 cells are allogeneic emTh-1 cells.

12. The use according to claim 9 wherein the source of disease antigens is CRCL.

13. The use according to claim 9 wherein the Th1 cells and the source of disease antigens are to be administered at least 3 times and at intervals of about 3-10 days until the patient exhibits a therapeutic effect.

~~14. A composition comprising a source of disease antigens and an adjuvant wherein the disease antigens are contained within chaperone proteins and the adjuvant comprises activated allogeneic Th1 cells.~~

~~15.~~14. Use of a source of disease antigens in the manufacture of a medicament for suppressing immune tolerance and promoting a therapeutic effect in a patient with a disease, wherein the patient has received activated Th1 cells, and wherein the Th1 cells and the disease antigens are to be administered at the same location.

~~16.~~15. The use according to claim 6, wherein the therapeutic composition further comprises chaperone rich cell lysate of the disease antigens.